Lineage Cell Therapeutics (LCTX) Other Working Capital Changes (2010 - 2026)

Lineage Cell Therapeutics has reported Other Working Capital Changes for 17 years, with the latest figure at -$995000.0 in Q1 2026.

• For the quarter ending Q1 2026, Other Working Capital Changes rose 22.2% year-over-year to -$995000.0; the trailing twelve-month figure through Mar 2026 stood at $238000.0 (up 102.72% YoY), and the FY2025 full-year result was -$46000.0, up 99.4% from the prior year.
• Other Working Capital Changes for Q1 2026 stood at -$995000.0, down from $5.5 million in the prior quarter.
• The five-year high for Other Working Capital Changes was $11.1 million in Q4 2022, with the low at -$6.8 million in Q4 2024.
• Historically, Other Working Capital Changes has averaged -$514647.1 across 5 years, with a median of -$1.3 million in 2025.
• The largest YoY upside for Other Working Capital Changes was 1665.31% in 2022 against a maximum downside of 5388.04% in 2022.
• Lineage Cell Therapeutics' Other Working Capital Changes stood at $11.1 million in 2022, then tumbled by 95.75% to $474000.0 in 2023, then plunged by 1532.28% to -$6.8 million in 2024, then jumped by 181.71% to $5.5 million in 2025, then plunged by 117.94% to -$995000.0 in 2026.
• The last three Other Working Capital Changes figures came in at -$995000.0 (Q1 2026), $5.5 million (Q4 2025), and -$4.3 million (Q3 2025), per Business Quant data.